The Indian pharmaceutical industry has emerged as a global leader, driven by R&D, innovation, and strong export performance. Valued at USD 130 billion by 2030, the sector recorded 6.8% domestic growth in 2023 and a 9.67% rise in exports to USD 27.9 billion in FY 2023–24. India hosts the largest number of US FDA–approved manufacturing sites outside the US, reinforcing global trust. With increasing investments, strategic collaborations, and a growing footprint in generics, India's pharma sector is poised for sustained expansion. This White Paper explores the regulatory, structural, and market dynamics shaping its future.
View PDF
Download PDF
